ImmPORT Therapeutics

ImmPORT Therapeutics is a biotechnology company pioneering the development of a new class of therapeutics targeting the Nuclear Pore Complex (NPC). Founded on the groundbreaking research of Dr. Dirk Görlich at the Max Planck Institute, the company utilizes proprietary nanobody technology to selectively modulate nuclear transport pathways that are dysregulated in cancer and autoimmune diseases. By targeting specific nucleoporins, ImmPORT aims to restore normal cellular function with higher precision and lower toxicity than broad-spectrum nuclear export inhibitors. The company is backed by premier life science investors, including ARCH Venture Partners and F-Prime Capital, and is currently advancing its lead programs through pre-clinical development.